ATE428777T1 - Muskelspezifische expressionsvektoren - Google Patents
Muskelspezifische expressionsvektorenInfo
- Publication number
- ATE428777T1 ATE428777T1 AT02739449T AT02739449T ATE428777T1 AT E428777 T1 ATE428777 T1 AT E428777T1 AT 02739449 T AT02739449 T AT 02739449T AT 02739449 T AT02739449 T AT 02739449T AT E428777 T1 ATE428777 T1 AT E428777T1
- Authority
- AT
- Austria
- Prior art keywords
- muscle
- promoter
- elements
- expression vectors
- specific expression
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title 1
- 210000003205 muscle Anatomy 0.000 abstract 4
- 239000003623 enhancer Substances 0.000 abstract 3
- 102100036912 Desmin Human genes 0.000 abstract 2
- 108010044052 Desmin Proteins 0.000 abstract 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 abstract 2
- 102000013394 Troponin I Human genes 0.000 abstract 2
- 108010065729 Troponin I Proteins 0.000 abstract 2
- 210000005045 desmin Anatomy 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 abstract 1
- 210000000107 myocyte Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29330401P | 2001-05-24 | 2001-05-24 | |
| PCT/US2002/016748 WO2002095006A2 (en) | 2001-05-24 | 2002-05-22 | Muscle-specific expression vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE428777T1 true ATE428777T1 (de) | 2009-05-15 |
Family
ID=23128549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02739449T ATE428777T1 (de) | 2001-05-24 | 2002-05-22 | Muskelspezifische expressionsvektoren |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030100526A1 (OSRAM) |
| EP (2) | EP1390490B1 (OSRAM) |
| JP (1) | JP2004535801A (OSRAM) |
| AT (1) | ATE428777T1 (OSRAM) |
| CA (1) | CA2448120A1 (OSRAM) |
| DE (1) | DE60231975D1 (OSRAM) |
| WO (1) | WO2002095006A2 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157064A1 (en) * | 2001-11-09 | 2003-08-21 | Pascal Neuville | Chimeric promoters for controlling expression in muscle cells |
| US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
| US8557969B2 (en) | 2004-12-01 | 2013-10-15 | The Regents Of The University Of Michigan | Compositions and methods for regulating cardiac performance |
| WO2008054713A2 (en) * | 2006-10-30 | 2008-05-08 | Thomas Jefferson University | Tissue specific gene therapy treatment |
| US20120322861A1 (en) * | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| CA2834729A1 (en) | 2011-04-06 | 2012-10-11 | Universite Pierre Et Marie Curie (Paris 6) | A skeletal muscle-specific enhancer |
| KR20150020250A (ko) | 2012-06-19 | 2015-02-25 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 당뇨병을 치료하기 위한 조성물 및 방법 |
| US9845465B2 (en) | 2012-08-15 | 2017-12-19 | University Of Virginia Patent Foundation | Compositions and methods for treating peripheral arterial disease |
| WO2014100714A1 (en) | 2012-12-20 | 2014-06-26 | Sarepta Therapeutics, Inc. | Improved exon skipping compositions for treating muscular dystrophy |
| KR20250047401A (ko) | 2013-03-14 | 2025-04-03 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| KR20240094032A (ko) | 2013-03-14 | 2024-06-24 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| WO2015035364A1 (en) * | 2013-09-09 | 2015-03-12 | University Of Washington Through Its Center For Commercialization | Proteins for targeting neuronal nitric oxide synthase to muscle sarcolemma and related methods of use |
| SG11201605906UA (en) | 2014-01-21 | 2016-08-30 | Univ Bruxelles | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
| KR102458219B1 (ko) | 2015-03-05 | 2022-10-24 | 피터 운드 트라우들 앵겔호른-스티프텅 주르 푀르데룽 데르 레벤스위센샤프텐 | 세포 표면 상에 펩타이드를 제시하기 위한 시스템 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CN104894651B (zh) * | 2015-06-29 | 2017-04-12 | 天津诺禾医学检验所有限公司 | 微量起始dna的高通量测序文库构建方法及其所构建的高通量测序文库 |
| HK1257519A1 (zh) * | 2015-09-17 | 2019-10-25 | Research Institute At Nationwide Children's Hospital | 用於 galgt2 基因治療的方法和物質 |
| CA3020754C (en) | 2016-04-14 | 2023-07-25 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
| EP3471544B1 (en) | 2016-06-21 | 2021-12-22 | The Curators Of The University Of Missouri | Modified dystrophin proteins |
| CA3071978A1 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| WO2019153009A1 (en) | 2018-02-05 | 2019-08-08 | Audentes Therapeutics, Inc. | Transcription regulatory elements and uses thereof |
| JP7467356B2 (ja) * | 2018-02-07 | 2024-04-15 | ジェネトン | ハイブリッド調節要素 |
| CA3097192A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
| EP3793616A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US12319929B2 (en) | 2018-05-15 | 2025-06-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| US12060567B2 (en) | 2018-06-13 | 2024-08-13 | Voyager Therapeutics, Inc. | Engineered untranslated regions (UTR) for AAV production |
| US20210254103A1 (en) | 2018-07-02 | 2021-08-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| US20210348242A1 (en) | 2018-10-04 | 2021-11-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US20210395777A1 (en) | 2018-10-15 | 2021-12-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
| MX2021005720A (es) | 2018-11-16 | 2021-07-21 | Astellas Pharma Inc | Metodo para tratar la distrofia muscular mediante el direccionamiento del gen de utrofina. |
| JP2022522995A (ja) | 2019-01-18 | 2022-04-21 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖ粒子を生成するための方法及びシステム |
| AU2020229886B2 (en) | 2019-02-28 | 2025-09-18 | Benitec IP Holdings Inc. | Compositions and methods for treating oculopharyngeal muscular dystrophy (OPMD) |
| KR20210148273A (ko) * | 2019-04-08 | 2021-12-07 | 제네똥 | 근육 발현을 위한 하이브리드 프로모터 |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| BR112021023899A2 (pt) | 2019-05-28 | 2022-01-18 | Astellas Pharma Inc | Método para o tratamento da distrofia muscular por direcionamento ao gene da dmpk |
| KR20220045013A (ko) | 2019-08-16 | 2022-04-12 | 가부시키가이샤 모달리스 | Lama1 유전자를 표적으로 하는 근이영양증의 치료 방법 |
| WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| EP4126910A1 (en) | 2020-04-01 | 2023-02-08 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| BR112022020753A2 (pt) | 2020-04-15 | 2022-12-20 | Voyager Therapeutics Inc | Compostos de ligação a tau |
| PE20230767A1 (es) | 2020-05-13 | 2023-05-09 | Voyager Therapeutics Inc | Redireccion del tropismo de las capsides de aav |
| WO2021230385A1 (en) | 2020-05-15 | 2021-11-18 | Astellas Pharma Inc. | Method for treating muscular dystrophy by targeting utrophin gene |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| CA3192120A1 (en) * | 2020-09-11 | 2022-03-17 | James A. Williams | Muscle-specific hybrid promoter |
| US20220098615A1 (en) | 2020-09-30 | 2022-03-31 | NGGT, Inc. | Dual functional expression vectors and methods of use thereof |
| EP4228610A1 (en) | 2020-10-13 | 2023-08-23 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| WO2022114243A1 (en) | 2020-11-25 | 2022-06-02 | Astellas Pharma Inc. | Method for treating muscular dystrophy by targeting dmpk gene |
| EP4284936A1 (en) | 2021-01-26 | 2023-12-06 | Kriya Therapeutics, Inc. | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same |
| EP4036238A1 (en) * | 2021-01-27 | 2022-08-03 | The University Court of the University of Edinburgh | Functional nucleic acid molecule and method |
| WO2022174113A1 (en) | 2021-02-12 | 2022-08-18 | Merand Pharmaceuticals, Inc. | Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders |
| WO2022187679A1 (en) | 2021-03-04 | 2022-09-09 | Kriya Therapeutics, Inc. | Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same |
| CA3226119A1 (en) * | 2021-08-04 | 2023-02-09 | Giuseppe RONZITTI | Hybrid promoters for gene expression in muscles and in the cns |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| CN118317944A (zh) | 2021-09-14 | 2024-07-09 | 雷纳嘉德医疗管理公司 | 非环状脂质及其使用方法 |
| CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| MX2024008509A (es) | 2022-01-09 | 2024-07-19 | Kriya Therapeutics Inc | Construcciones de vectores para la distribucion de acidos nucleicos que codifican anticuerpos terapeuticos anti-igf-1r y metodos para usarlos. |
| US20250243510A1 (en) * | 2022-03-16 | 2025-07-31 | Rutgers, The State University Of New Jersey | Controlled muscle-specific gene delivery |
| WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
| EP4522757A2 (en) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250243263A1 (en) | 2022-06-22 | 2025-07-31 | Voyager Therapeutics, Inc. | Tau binding compounds |
| US20260009003A1 (en) * | 2022-07-11 | 2026-01-08 | Vita Therapeutics, Inc. | Manufacturing of therapeutic satellite cells for treating muscular dystrophy |
| AU2023342086A1 (en) | 2022-09-15 | 2025-03-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2025014832A1 (en) | 2023-07-07 | 2025-01-16 | Kriya Therapeutics, Inc. | Periocular delivery of aav vectors for treating ophthalmic pathologies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266488A (en) * | 1988-04-06 | 1993-11-30 | The Regents Of The University Of California | Troponin T gene promoter and derivatives thereof |
| US5795872A (en) * | 1995-09-19 | 1998-08-18 | Pharmadigm, Inc. | DNA construct for immunization |
| US5846528A (en) * | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
| US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
| ES2219011T3 (es) * | 1998-04-24 | 2004-11-16 | University Of Florida | Vector viral adeno-asociado recombinante que codifica alfa-1 antitripsina para terapia genica. |
| ATE437944T1 (de) * | 2000-04-28 | 2009-08-15 | Asklepios Biopharmaceutical In | Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung |
| WO2001083703A2 (en) * | 2000-05-04 | 2001-11-08 | California Institute Of Technology | Checkpoint-activating oligonucleotides |
-
2002
- 2002-05-22 EP EP02739449A patent/EP1390490B1/en not_active Expired - Lifetime
- 2002-05-22 DE DE60231975T patent/DE60231975D1/de not_active Expired - Lifetime
- 2002-05-22 EP EP08103273A patent/EP2017338A1/en not_active Withdrawn
- 2002-05-22 CA CA002448120A patent/CA2448120A1/en not_active Abandoned
- 2002-05-22 AT AT02739449T patent/ATE428777T1/de not_active IP Right Cessation
- 2002-05-22 WO PCT/US2002/016748 patent/WO2002095006A2/en not_active Ceased
- 2002-05-22 JP JP2002592469A patent/JP2004535801A/ja active Pending
- 2002-05-24 US US10/156,604 patent/US20030100526A1/en not_active Abandoned
-
2007
- 2007-03-12 US US11/716,899 patent/US20110212529A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004535801A (ja) | 2004-12-02 |
| EP2017338A1 (en) | 2009-01-21 |
| EP1390490A2 (en) | 2004-02-25 |
| CA2448120A1 (en) | 2002-11-28 |
| US20030100526A1 (en) | 2003-05-29 |
| DE60231975D1 (de) | 2009-05-28 |
| EP1390490A4 (en) | 2005-05-11 |
| WO2002095006A2 (en) | 2002-11-28 |
| US20110212529A1 (en) | 2011-09-01 |
| EP1390490B1 (en) | 2009-04-15 |
| WO2002095006A3 (en) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE428777T1 (de) | Muskelspezifische expressionsvektoren | |
| EA200100411A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| BR0008056A (pt) | Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas | |
| BR9804474B1 (pt) | processo para a preparaÇço de Éteres cÍclicos com cinco membros ou com seis membros, especialmente de anidropoliàis e mistura de anidrohexitol. | |
| DE69435038D1 (de) | Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie | |
| ATE217629T1 (de) | Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel | |
| TR200101549T2 (tr) | p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar. | |
| DK0934310T3 (da) | Thiosyreafledte, monocykliske forbindelser som antikoaguleringsmidler | |
| DE69329304D1 (de) | Enzymatische Verfahren zur Resolution von Enantiomeren-Mischungen nützlich wie Zwischenprodukte zur Herstellung von Taxanen | |
| DK1026533T3 (da) | Progressive additionslinser med regressive overflader | |
| BR0209149A (pt) | Ftalazinonas | |
| EA200400006A1 (ru) | Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов | |
| DE69400887D1 (de) | Sulphonamid-Derivate | |
| EA200100012A1 (ru) | Мостиковые инденопирролокарбазолы | |
| EA200201083A1 (ru) | Противоопухолевые производные эктейнасцидина | |
| ATE378073T1 (de) | Von cyclodextrinen stabilisierter radiopharmazeutischer reagenzsatz | |
| EA200000320A1 (ru) | Изохинолины в качестве ингибиторов урокиназы | |
| ATE460923T1 (de) | Lyophilisierung von virosomen | |
| CY1109592T1 (el) | 5-υποκατεστημενα παραγωγα πυριμιδινης νουκλεοζιτικων αναλογων με κλειδωμα διαμορφωσης | |
| DE69610628D1 (de) | N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide | |
| EA200000519A1 (ru) | 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ | |
| DE60334839D1 (de) | Hybridpolymerase-verfahren und -zusammensetzungen | |
| EA199900944A1 (ru) | Гемисульфат карбоциклического нуклеозида и его применение в лечении вирусных инфекций | |
| ATE236888T1 (de) | N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide | |
| EA200000520A1 (ru) | 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |